HORIZON-MISS-2027-02-CANCER-03:
Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes (RIA)
Deadline:
♦ Cross-cutting priorities:
♦ Type of MGA:
♦ Procedure:
♦ Specific condition:
